Diabetes drug choice may influence outcomes after liver cancer surgery

Clinical takeaway: For patients with type 2 diabetes undergoing curative resection for hepatocellular carcinoma, consider GLP-1 receptor agonists when clinically appropriate. These observational findings suggest postoperative diabetes medication choice may influence long-term cancer outcomes.

Recurrence remains common after curative-intent resection for hepatocellular carcinoma (HCC), even after complete tumor removal. Because many patients with HCC also have type 2 diabetes, whether the choice of glucose-lowering therapy affects long-term oncologic outcomes has become an important clinical question.

In this multicenter target trial emulation study, investigators compared postoperative initiation of GLP-1 receptor agonists (GLP-1RAs) with dipeptidyl peptidase-4 (DPP-4) inhibitors in 1,249 adults with type 2 diabetes who underwent curative liver resection for HCC. Patients initiated one of the two drug classes within 90 days after surgery and were followed for a median of 50.8 months.

Compared with DPP-4 inhibitors, GLP-1RAs were associated with a 20% lower relative risk of cancer recurrence and a 42% lower relative risk of death.

The findings add to growing evidence that GLP-1RAs may provide benefits beyond glycemic control, raising the possibility that diabetes medication selection could also influence long-term cancer outcomes in patients undergoing curative HCC resection. How these benefits occur is not yet fully understood, although reduced inflammation, improved insulin sensitivity, and direct effects on tumor biology have been proposed.

Postoperative GLP-1 receptor agonist use was associated with delayed recurrence and longer survival than DPP-4 inhibitor use after curative liver resection for hepatocellular carcinoma, although prospective confirmation is needed, concluded the study authors.

Source: Xiang Y-J, et al. (2026 July 9) Hepatology. Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study